Session Objectives

1. Describe regulatory and industry perspectives on quality clinical trials.

2. Identify key 483 observations related to inadequate sponsor oversight and monitoring practices.

3. Learn precision monitoring and auditing strategies and tools for efficient and effective clinical trial process.
Disclaimer

• The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not be attributed to Drug Information Association, Inc. (“DIA”), its directors, officers, employees, volunteers, members, chapters, councils, Special Interest Area Communities or affiliates, or any organization with which the presenter is employed or affiliated.

• These PowerPoint slides are the intellectual property of the individual presenter and are protected under the copyright laws of the United States of America and other countries. Used by permission. All rights reserved. Drug Information Association, DIA and DIA logo are registered trademarks or trademarks of Drug Information Association Inc. All other trademarks are the property of their respective owners.
Monitoring and auditing are effective risk management tools
Discussion Points:

- Regulatory and Industry perspectives on effective monitoring and auditing of clinical trials
- The role of monitoring and auditing in risk management
- Essential monitoring and auditing tools for quality clinical trials
Definitions

- **Monitoring** – *The act of overseeing the progress of a clinical trial, and of ensuring that it is conducted, recorded, and reported in accordance with the protocol, standard operating procedures (SOPs), GCP, and the applicable regulatory requirement(s).*
Definitions

• **Auditing**—a systematic and independent examination of trial-related activities and documents to determine whether the evaluated trial-related activities were conducted, and the data were recorded, analyzed, and accurately reported according to the protocol, sponsor’s standard operating procedures (SOPs), good clinical practice (GCP), and the applicable regulatory requirement(s).
Regulatory Perspective

• Inadequate monitoring cited on Form FDA 483

• FDA Guidance Document on monitoring Clinical Investigators

• QA activities not a regulatory requirement for clinical trial operations BUT implied
Sponsor Perspective

– Responsible for ensuring proper monitoring of the investigation(s)
– Responsible for selecting monitors qualified by training and experience
– Monitor’s responsibilities and monitoring procedures are described in ICHE6
– Responsible for implementing quality assurance (i.e. audits) as described in ICHE6
Investigator Perspective

- Responsible for receiving and responding to monitoring and auditing visits
- Responsible for managing the study in order to control risks and to ensure contingencies are in place for the occurrence of any adverse events
Strategic Imperatives

• Organizations must continue to increase efficiency, quality, compliance as they continue to decrease cost

• Management must proactively gather and analyze data to assess people, processes and technological effectiveness and efficiencies
Operational Imperatives

• Organizations has to be ready for increased scrutiny of all their operations and data

• Collaborative approach to identify key processes, quality goals and metrics

• Quality improvement plans provide quantitative data to support better communication within the organization
Monitoring Issues

• Monitoring visit issues not escalated or resolved in a timely manner
• Inadequate source data verification (SDV)
• Inadequate clinical supply chain management and investigational product (IP) reconciliation (i.e. expiry date, forecasting supply)
• Inadequate qualifications and training of monitors
Auditing Issues

- Ineffective audit plan
- Trend and root cause analysis not performed
- No defined process for escalation of significant findings and accountability for remediation
- Inadequate qualifications and training of auditors
## Monitoring Strategies and Tools

<table>
<thead>
<tr>
<th>Activity</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>TMF creation and maintenance</strong></td>
<td>Assists sponsor in maintaining required essential documents. Electronic TMF allows sponsor-CRO visibility</td>
</tr>
<tr>
<td><strong>Clinical supply management</strong></td>
<td>Develop procedures or clinical supply relabeling/expiry date management; develop automated tool for demand/supply forecasting/tracking/reconciliation (e.g. IVRS, EDC)</td>
</tr>
<tr>
<td><strong>CRF-source verification</strong></td>
<td>Direct method of verifying data transcribed on CRFs are consistent with source document by reviewing actual source data vs. photocopies</td>
</tr>
<tr>
<td><strong>Source data verification (SDV)</strong></td>
<td>SOP and or monitoring plan giving precise instructions on how the monitor should undertake SDV</td>
</tr>
<tr>
<td><strong>Investigator compliance</strong></td>
<td>Adopt an automated clinical trial management system (CTMS) and standard for site qualifications and training</td>
</tr>
</tbody>
</table>
## Auditing Strategies and Tools

<table>
<thead>
<tr>
<th>Activity</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Audit Strategy</td>
<td>Describes type of audits to be performed (e.g. system, site audit supplier) critical phase selection (i.e. pivotal phase III).</td>
</tr>
<tr>
<td>Audit Plan</td>
<td>Describes scope of a QA audit schedule, identifies audit team, outlines audit standards (e.g. FDA GCP/ICH, protocol)</td>
</tr>
<tr>
<td>Audit Technique</td>
<td>i.e. FDA CP, “Story Approach” links process with performance</td>
</tr>
<tr>
<td>Process Audits</td>
<td>Evidence QC performed at each operational stage of the study</td>
</tr>
<tr>
<td>Site Audits</td>
<td>Assures protocol and GCP compliance</td>
</tr>
<tr>
<td>Audit Report</td>
<td>Evaluate/categorize audit findings for trend analysis</td>
</tr>
<tr>
<td>CAPA process</td>
<td>Discrepancies are tracked/prioritized for root cause analysis/corrective action</td>
</tr>
</tbody>
</table>
Summary

• The manner in which we conduct clinical trials is under scrutiny by FDA
• Efficient and effective monitoring is key to assuring quality clinical trials
• FDA’s inspectional approach appears to reflect principles of a QMS
• Regulatory compliance with GCP principles and best practices can be assured by adopting a risk management program
THANK YOU!

Jan Holladay Pierre, MPH
Quintiles Consulting

j.pierre@quintiles.com